Prostate Cancer Treatment Pluvicto Currently in Shortage
Pluvicto is indicated for patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.
Diagnosis & Disease Information
Tecentriq Indication for Previously Untreated Advanced Bladder Cancer Withdrawn
The decision to withdraw the indication was made based on findings from the subsequent confirmatory phase 3 IMvigor130 trial.
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
Olaparib + Abiraterone Gets Priority Review for Castration-Resistant Prostate Cancer
The sNDA is supported by data from the phase 3 PROpel trial which included adults with mCRPC in the first-line setting.
New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer
The approval was based on data from the phase 3 ARASENS trial.
Trial Evaluating Nivolumab Plus Ipilimumab for Localized RCC Misses Endpoint
The CheckMate -914 trial included patients with localized RCC who underwent radical or partial nephrectomy and who were at high risk of relapse.
Sesen Bio Puts Development of Bladder Cancer Drug Vicineum on Pause
The Biologics License Application (BLA) for Vicineum included preliminary findings from the phase 3 VISTA trial.
Trials Investigating Bempegaldesleukin in Combination With Nivolumab Discontinued
The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
Anxiety, Depression Med Use Linked to Increased Odds of PSA Testing
Researchers used 2018 data from the National Health Interview Survey to investigate the association.
Bladder-Sparing Therapies for Localized Muscle-Invasive Bladder Cancer Compared
The real-world study compared the efficacy of neoadjuvant chemotherapy plus immunotherapy vs chemotherapy alone in patients with cT2-4bN0-3M0-1a pathological and imaging diagnosed MIBC.
- Loading...
Loading...
Next post in Bladder Cancer
Loading... 
Loading...